Serum CA-125 is the only validated serum marker for uterine (endometrial) cancer, but it has significant limitations and is NOT useful for diagnosis or screening.
CA-125 should only be used for monitoring treatment response in patients with known extrauterine disease, not for initial diagnosis or screening. 1, 2
Key Clinical Points
CA-125 Limitations for Diagnosis
- CA-125 has NO diagnostic value for endometrial cancer 3
- Only ~50% of stage I endometrial cancer patients have elevated CA-125 4
- True-positive rate increases to 80% only with stage II or greater disease 4
- False positives occur with:
Appropriate Use of CA-125
Use CA-125 only in these specific scenarios:
- Monitoring clinical response in patients with confirmed extrauterine disease 1, 5, 6, 2
- Predicting extrauterine extension when levels >35 U/mL 3
- Prognostic correlation (though clinical benefit unclear) 3
Do NOT use CA-125 for:
- Screening asymptomatic women 1, 2
- Initial diagnosis of endometrial cancer 3
- Detecting isolated vaginal metastases (may be normal) 1, 5
- Predicting recurrence without other clinical findings 1, 5
Emerging Research Markers (Not Yet Validated)
Recent research has identified potential biomarkers, but none are currently recommended for clinical use:
HE4 (Human Epididymis Protein 4)
- Shows promise for predicting recurrence and risk stratification 7, 8
- May be superior to CA-125 for detecting lymph node invasion 8
- Not yet validated for routine clinical practice
Other Investigational Markers
- IL-4, IL-7, IL-9, NT, NRP1 9
- Lipid panels 10
- Exosomal proteins (APOA1, HBB, CA1, PF4V1) 11
- All remain research tools only
Clinical Algorithm
For suspected endometrial cancer:
- Diagnosis requires tissue: Office endometrial biopsy (90% sensitive) 1, 2
- If biopsy negative but symptoms persist → fractional D&C under anesthesia 1, 2
- Do NOT order CA-125 for diagnosis
- Reserve CA-125 for monitoring only if extrauterine disease confirmed at surgery
Currently, no validated screening test exists for endometrial cancer 1, 5, 2
Critical Pitfall
The most common error is ordering CA-125 for diagnosis or screening. This leads to false reassurance when normal (missing 50% of early cancers) or unnecessary anxiety with false positives from benign conditions. Tissue diagnosis through endometrial biopsy remains the gold standard.